
Traws Pharma (TRAW) Stock Forecast & Price Target
Traws Pharma (TRAW) Analyst Ratings
Bulls say
Traws Pharma is currently going through regulatory hurdles and studies to potentially restart the TXM program, which could provide a major de-risking event for investors. Despite the potential for setbacks with the FDA's clinical hold, management is actively working to resolve the issues and the company is also pursuing an alternate path for generating human proof-of-concept data through a U.K. challenge study. Additionally, Traws Pharma's plans to reposition TXM as a once-monthly prophylactic agent for seasonal influenza prevention expands its commercial potential and adds to the company's overall value.
Bears say
Traws Pharma is a clinical-stage biopharmaceutical company with four clinical programs focusing on developing antiviral agents. However, the company's negative outlook is driven by concerns over its funding solution beyond 1Q27, as well as various risks such as financing, clinical trial, regulatory, delisting, and bankruptcy. These concerns outweigh the potential upside from pipeline success and a potential large market for COVID, hantavirus, or Ebola. Overall, the company may face challenges in achieving profitability in the near future.
This aggregate rating is based on analysts' research of Traws Pharma and is not a guaranteed prediction by Public.com or investment advice.
Traws Pharma (TRAW) Analyst Forecast & Price Prediction
Start investing in Traws Pharma (TRAW)
Order type
Buy in
Order amount
Est. shares
0 shares